中国当代医药
中国当代医药杂志欢迎您 今天是   2025年1月23日星期四
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2022, Vol. 29 Issue (27): 90-92转96    
  肿瘤医学 本期目录 | 过刊浏览 | 高级检索 |
胸腔镜肺癌根治术治疗复发性肺癌患者术后应激反应的效果
吴凯
湖北省江汉油田总医院心胸甲乳外科,湖北潜江 433124
Effect of thoracoscopic radical resection of lung cancer on postoperative stress response in patients with recurrent lung cancer
WU Kai
Department of Cardiothoracic Thyroid and Breast Surgery, Jianghan Oilfield General Hospital, Hubei Province, Qianjiang 433124, China
全文: PDF (775 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨胸腔镜肺癌根治术治疗在复发性肺癌患者术后应激反应中的应用效果。 方法 选取2019年2月至2020年1月于湖北省江汉油田总医院心胸甲乳外科就诊的80 例复发性肺癌患者作为研究对象,采用随机数字表法将其分为对照组(40 例)和试验组(40 例)。对照组患者采用传统开胸术进行治疗,试验组患者采用胸腔镜肺癌根治术进行治疗。比较两组患者的应激反应指标及炎症反应指标,记录两组患者的各项手术指标、临床治疗效果。结果 试验组治疗后应激反应指标中的皮质醇、生长激素、前列腺素E2 水平低于对照组治疗后,差异有统计学意义(P<0.05)。试验组治疗后炎症反应指标中的C 反应蛋白(CRP)、降钙素原(PCT)、白介素-6(IL-6)水平低于对照组治疗后,差异有统计学意义(P<0.05)。试验组治疗后的治疗总有效率高于对照组治疗后,差异有统计学意义(P<0.05)。试验组的胸腔管留置时间短于对照组,差异有统计学意义(P<0.05)。结论 将胸腔镜肺癌根治术做为主方案治疗复发性肺癌可以明显提高患者的治疗效果和治疗安全性,缩短胸腔管留置时间,优化应激及炎症反应,可在临床中推广应用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
吴凯
关键词 肺癌胸腔镜下手术应激反应指标有效率    
Abstract:Objective To investigate the application effect of thoracoscopic radical resection of lung cancer in postoperative stress response in patients with recurrent lung cancer. Methods A total of 80 patients with recurrent lung cancer who visited the Department of Cardiothoracic Thyroid and Breast Surgery of Jianghan Oilfield General Hospital in Hubei Province from February 2019 to January 2020 were selected as the research objects, and they were divided into the control group (40 cases) and the experimental group (40 cases) according to random number table method. The patients in the control group were treated with traditional thoracotomy, and the patients in the experimental group were treated with thoracoscopic radical resection of lung cancer. The stress response indicators and inflammatory reaction indexes of the two groups were compared, and the surgical indexes and clinical treatment effects of the two groups were recorded. Results The levels of cortisol, growth hormone and prostaglandin E2 in the stress response indexes of the experimental group after treatment were lower than those of the control group after treatment, and the differences were statistically significant (P<0.05). After treatment, the levels of C-reactive protein (CPR), procalcitonin (PCT) and interleukin-6 (IL-6) in the inflammatory response indexes in the experimental group were lower than those in the control group after treatment, and the differences were statistically significant (P<0.05). The treatment total effective rate of the experimental group after treatment was higher than that of the control group after treatment, and the difference was statistically significant (P<0.05). The indwelling time of the chest tube in the experimental group was shorter than that in the control group, and the difference was statistically significant (P<0.05). Conclusion Thoracoscopic radical resection of lung cancer as the main regimen in the treatment of recurrent lung cancer can significantly improve the therapeutic effect and safety of patients, shorten the indwelling time of thoracic tube, optimize stress and inflammatory response, and it can be popularized and applied in clinical practice.
Key wordsLung cancer    Thoracoscopic surgery    Stress response index    Effective rate
    
引用本文:   
吴凯. 胸腔镜肺癌根治术治疗复发性肺癌患者术后应激反应的效果[J]. 中国当代医药, 2022, 29(27): 90-92转96.
WU Kai. Effect of thoracoscopic radical resection of lung cancer on postoperative stress response in patients with recurrent lung cancer. 中国当代医药, 2022, 29(27): 90-92转96.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2022/V29/I27/90
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载